GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,691.20
+15.20 (+0.91%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous close1,676.00
Open1,692.60
Bid1,694.80 x 0
Ask1,696.40 x 0
Day's range1,687.80 - 1,702.20
52-week range1,408.80 - 1,749.40
Volume5,629,496
Avg. volume8,543,045
Market cap84.364B
Beta (3Y monthly)0.85
PE ratio (TTM)19.05
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.76 (4.53%)
Ex-dividend date2019-08-08
1y target estN/A
  • Do GlaxoSmithKline's (LON:GSK) Earnings Warrant Your Attention?
    Simply Wall St.

    Do GlaxoSmithKline's (LON:GSK) Earnings Warrant Your Attention?

    For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

  • Reuters - UK Focus

    UPDATE 2-GSK builds oncology pipeline as drug shown to help myeloma patients

    GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

  • GSK builds oncology pipeline as drug shown to help myeloma patients
    Reuters

    GSK builds oncology pipeline as drug shown to help myeloma patients

    Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion (£4.2 billion) last year and an agreement in February to pay up to 3.7 billion euros (£3.3 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

  • Is the GSK share price worth buying?
    Fool.co.uk

    Is the GSK share price worth buying?

    GlaxoSmithKline plc (LON: GSK) has posted some good results. But is it worth investing in?

  • GSK's long acting HIV injection gets boost from study
    Reuters

    GSK's long acting HIV injection gets boost from study

    ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combinations and will use the lower drug burden in comparison with three-drug cocktails such as Gilead's Biktarvy as its main selling point to patients and physicians. It is banking on longer-term studies to yield hard evidence of fewer side effects over time.

  • Reuters - UK Focus

    MORNING BID EUROPE-To cut or not to cut, that is the question

    Target shares surged 20% and Lowe jumped 10%, helping lift Wall Street almost 1% on the day. The Federal Reserve board doesn’t seem to think so -- the July meeting minutes yesterday showed members united in wanting to signal they were not on a pre-set path to more easing. If we get more of that hawkish bent from Fed Chairman Jerome Powell at Jackson Hole tomorrow, it could well dash hopes for a prolonged easing cycle.

  • Reuters - UK Focus

    UPDATE 2-GSK's long acting HIV injection gets boost from study

    GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences. GSK's two-drug injection was as effective as a monthly dose of the same regimen in maintaining viral suppression at 48 weeks in a late-stage study, said ViiV Healthcare, GSK's HIV unit. ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combinations and will use the lower drug burden in comparison with three-drug cocktails such as Gilead's Biktarvy as its main selling point to patients and physicians.

  • Reuters - UK Focus

    LIVE MARKETS-Heebie-jeebies ahead of PMI data, Brexit, Jackson Hole summit

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Stock futures indicate a weak open in Europe as anxious investors avoid risky bets ahead of UK PM Boris Johnson's meeting with France's Macron today on Brexit, August PMI data from key euro-zone economies and the Jackson Hole summit on Friday. Eurostoxx futures are down 0.2% and the CAC and DAX futures are down 0.3%.

  • Think like Warren Buffett! 2 dividend stocks I’d buy as the FTSE 100 collapses
    Fool.co.uk

    Think like Warren Buffett! 2 dividend stocks I’d buy as the FTSE 100 collapses

    Don't shrink in the face of diving investor confidence. Grab your debit card and get a slice of these undervalued FTSE 100 (INDEXFTSE: UKX) income heroes, says Royston Wild.

  • Better Buy: Eli Lilly vs. GlaxoSmithKline
    Motley Fool

    Better Buy: Eli Lilly vs. GlaxoSmithKline

    Which stock wins in this big-pharma matchup?

  • Ionis Pharmaceuticals Looks to Partners to Pay the Bills
    Motley Fool

    Ionis Pharmaceuticals Looks to Partners to Pay the Bills

    Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.

  • Forget 1% from a Cash ISA: I’d pick up 5%+ from these 2 FTSE 100 dividend shares
    Fool.co.uk

    Forget 1% from a Cash ISA: I’d pick up 5%+ from these 2 FTSE 100 dividend shares

    These two FTSE 100 (INDEXFTSE:UKX) stocks could deliver significantly higher income returns than a Cash ISA in my opinion.

  • Reuters - UK Focus

    AstraZeneca scores win in race to treat ovarian cancer

    AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer. Astra said on Wednesday its Lynparza drug, which blocks a cancer's ability to repair its genetic code during cell division, was shown to slow the progression of ovarian cancer that has started to spread in the body. The patient group that was examined in the so-called Paola-1 trial had been successfully given chemotherapy and Roche's Avastin as initial treatment following a diagnosis of advanced ovarian cancer.

  • Should Value Investors Consider GlaxoSmithKline (GSK) Stock?
    Zacks

    Should Value Investors Consider GlaxoSmithKline (GSK) Stock?

    Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

  • AnaptysBio Prepares for a Potential Gear Shift
    Motley Fool

    AnaptysBio Prepares for a Potential Gear Shift

    During the second quarter, the company upgraded the safety net under its lead candidate.

  • Reuters - UK Focus

    UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

    British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo. While Ebola is a deadly and contagious disease, it is also still relatively rare, making the potential market for a vaccine sporadic and very likely unprofitable. GSK's vaccine candidates - two designed to protect against Ebola and one against the Marburg virus - will be transferred to the Sabin Vaccine Institute in Washington, D.C., the British drugmaker said in a statement.

  • GSK ends development of Ebola vaccine, hands work to U.S. institute
    Reuters

    GSK ends development of Ebola vaccine, hands work to U.S. institute

    British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo. While Ebola is a deadly and contagious disease, it is also still relatively rare, making the potential market for a vaccine sporadic and very likely unprofitable. GSK's vaccine candidates - two designed to protect against Ebola and one against the Marburg virus - will be transferred to the Sabin Vaccine Institute in Washington, D.C., the British drugmaker said in a statement.

  • Reuters - UK Focus

    GSK hands work on potential Ebola vaccines to U.S. institute

    British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo. The vaccine candidates - two designed to protect against Ebola and one against the Marburg virus - will be transferred to the Sabin Vaccine Institute in Washington, D.C., GSK said in a statement. The deal will see Sabin continue to develop the candidate vaccines, one of which - a potential Ebola shot known as ChAd3 - has been through mid-stage, Phase II, trials in Africa and could possibly be used to halt or limit future Ebola epidemics.

  • Reuters - UK Focus

    IBM and other companies launch new blockchain network for supply management

    International Business Machines Corp announced on Monday a new blockchain network aimed at improving manual and cumbersome supply chain management. Supply chain management involves overseeing the flow of goods and services, such as tracking the movement and storage of raw materials, inventory, and finished goods. It has been identified as one area that can benefit from blockchain technology, a shared database maintained by a network of computers connected to the internet.

  • It Might Be Better To Avoid GlaxoSmithKline plc's (LON:GSK) Upcoming 1.1% Dividend
    Simply Wall St.

    It Might Be Better To Avoid GlaxoSmithKline plc's (LON:GSK) Upcoming 1.1% Dividend

    GlaxoSmithKline plc (LON:GSK) is about to trade ex-dividend in the next 2 days. You can purchase shares before the 8th...

  • Forget GlaxoSmithKline! 2 ‘better’ pharmaceutical stocks I think could help you retire in luxury
    Fool.co.uk

    Forget GlaxoSmithKline! 2 ‘better’ pharmaceutical stocks I think could help you retire in luxury

    Sure, GlaxoSmithKline plc (LON: GSK) has delivered some pretty decent shareholder returns over the past half a decade. But are these other medical marvels better buys today?

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes